---
figid: PMC9416350__vaccines-10-01249-g002
figtitle: 'Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic
  Targets as a New Approach for Breast Cancer: A Review'
organisms:
- Homo sapiens
- Mus musculus
- Vaccinia virus
- Vasconcellea candicans
pmcid: PMC9416350
filename: vaccines-10-01249-g002.jpg
figlink: /pmc/articles/PMC9416350/figure/vaccines-10-01249-f002/
number: F2
caption: 'Immunological mechanism of action of the peptide-based vaccines. After its
  administration, the peptides will be recognized by innate immune cells that promote
  the activation of the adaptive immune response (cellular and humoral). Released
  antibodies can promote the destruction of tumoral cells by ADCC, CDC, ADCP, signaling
  inhibition, and complement activation (classical pathway), whereas cytotoxic T cells
  can promote apoptosis of cancer cells by releasing perforins and granzymes or by
  interacting with Fas/FasL. APC: antigen-presenting cell; MHC-I: major histocompatibility
  complex type I; MHC-II: major histocompatibility complex type II; Th1: T helper
  1; Th2: T helper 2; ADCC: antibody-dependent cellular cytotoxicity; CDC: complement-dependent
  cytotoxicity; ADCP: antibody-dependent cellular phagocytosis. Image created in Biorender
  (https://biorender.com/ accessed on 2 July 2022).'
papertitle: 'Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic
  Targets as a New Approach for Breast Cancer: A Review.'
reftext: María Lilia Nicolás-Morales, et al. Vaccines (Basel). 2022 Aug;10(8):1249.
year: '2022'
doi: 10.3390/vaccines10081249
journal_title: Vaccines
journal_nlm_ta: Vaccines (Basel)
publisher_name: MDPI
keywords: peptide-based vaccines | breast cancer | therapeutic | tumor-associated
  antigens
automl_pathway: 0.9256863
figid_alias: PMC9416350__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC9416350__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9416350__vaccines-10-01249-g002.html
  '@type': Dataset
  description: 'Immunological mechanism of action of the peptide-based vaccines. After
    its administration, the peptides will be recognized by innate immune cells that
    promote the activation of the adaptive immune response (cellular and humoral).
    Released antibodies can promote the destruction of tumoral cells by ADCC, CDC,
    ADCP, signaling inhibition, and complement activation (classical pathway), whereas
    cytotoxic T cells can promote apoptosis of cancer cells by releasing perforins
    and granzymes or by interacting with Fas/FasL. APC: antigen-presenting cell; MHC-I:
    major histocompatibility complex type I; MHC-II: major histocompatibility complex
    type II; Th1: T helper 1; Th2: T helper 2; ADCC: antibody-dependent cellular cytotoxicity;
    CDC: complement-dependent cytotoxicity; ADCP: antibody-dependent cellular phagocytosis.
    Image created in Biorender (https://biorender.com/ accessed on 2 July 2022).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Trav6-3
  - Cd28
  - Cd80
  - Cd4
  - Hand2
  - Ccl4
  - Ccl3
  - Il5
  - Il4
  - Il9
  - Il6
  - Il10
  - Cxcl9
  - Cxcl10
  - Cxcl11
  - Fasl
  - Fas
  - Fasn
  - Igh-V7183
  - Igh-VS107
  - Ighv1-62
  - CD8A
  - CD8B
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD28
  - CD80
  - CD4
  - IL12A
  - IL12B
  - CCL4
  - CCL3
  - IL5
  - IL4
  - IL9
  - IL6
  - IL10
  - CXCL9
  - CXCL10
  - CXCL11
  - FASLG
  - FAS
  - HLA-C
  - FASN
---
